About this Organization
Medbox, Inc. is a publicly traded company that manufactures Medicine Dispensing Systems AKA Prescription Vending Machines. These machines are designed to automate the experience of purchasing cannabis from a dispensary and/or retail location. They were granted patents for their technology in both the United States and Canada.
Headquartered in West Hills, CA, Medbox has grossed $8 million dollars since it began doing business in 2010, and has opened office locations in Los Angeles, New York, Connecticut, Arizona, Toronto, London, & Tokyo.
Associates
Vincent Mehdizadeh
Founder
Vincent Mehdizadeh is the Founder & CEO of Medbox, Inc. and Medicine Dispensing Systems. He has received criticism for shortcomings in the past, but his companies have taken a stronghold in the cannabis community, particularly as far as publicly traded companies are concerned.
Similar Companies
Nuvilex, Inc.
Silver Spring, Maryland
Nuvilex is a biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live-cell encapsulation technology, called Cell-in-a-Box(TM). This unique technology will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes are being built. The Company’s treatment for pancreatic cancer involves the use of the widely used anticancer prodrug, ifosfamide, together with encapsulated live cells that convert ifosfamide into its active or “cancer-killing” form. Nuvilex’s subsidiary, Medical Marijuana Sciences, Inc., is dedicated to the development of cancer treatments based upon …
Plandai Biotechnology
Seattle, Washington
Based in Seattle, Plandai Biotechnology is a publicly-traded company that delivers highly bioavailable, phytonutrient rich extracts under the trademark, Phytofare™. In early 2014, Plandai submitted a request for ministerial dispensation to the Secretary of Parliament of South Africa, asking for the allowance of cannabis research. The company hopes to develop cannabis extract medicines for the treatment of cancer.
GW Pharmaceuticals (GWPH)
Porton Down, United Kingdom
GW Pharmaceuticals was founded in 1998 and is listed on both the NASDAQ Global Market (GWPH) and AIM, a market of the London Stock Exchange. GW is licensed by the UK Home Office to work with a range of controlled drugs for medical research purposes. The Group’s lead programme is the development of a product portfolio of cannabinoid prescription medicines to meet patient needs in a wide range of therapeutic indications, including Sativex® Oromucosal Spray and Epidiolex® for childhood epilepsy.
